MedTrace Logo

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

NCT00165451 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-07-07

No results posted yet for this study

Summary

This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer. These drugs are expected to target the blood vessels that supply the tumors with what they need to grow.

Conditions

  • Neoplasms

Interventions

DRUG

Thalidomide

Oral administration once daily at night starting at 3mg/Kg for 6 months.

DRUG

Celecoxib

Oral administration twice daily starting at 100mg/dose for 6 months.

DRUG

Etoposide

Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.

DRUG

Cyclophosphamide

Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.

Sponsors & Collaborators

Principal Investigators

  • Mark W. Kieran, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165451 on ClinicalTrials.gov